Albrecht M, Simon W E, Hölzel F
J Cancer Res Clin Oncol. 1985;109(3):210-6. doi: 10.1007/BF00390360.
Cell lines established from advanced mammary and ovarian carcinomas were assayed for the inhibition of in vitro proliferation by various antineoplastic drugs. The assays were performed with multiple experimental cultures derived from stock cultures of the tumor cell lines in early passages of the cultivation. As determined by comparison of the 50% inhibition of in vitro growth, differential sensitivity of the individual cell lines was observed. Based on the 2-h plasma level of the drugs as discriminatory threshold between resistance and sensitivity, the in vitro effectiveness of each drug on the individual cell lines was compared with the clinical results of chemotherapy applied to the corresponding patients. In total, positive in vitro/in vivo correlations were observed in 39 of 42 cases. The 17 cell lines evaluated retrospectively were resistant to those drugs which had been tried unsuccessfully during chemotherapy. Among the 25 cases tried prospectively 11 cases showed sensitivity in vitro and in vivo, and furthermore 11 prospective cases were resistant in vitro and in vivo.
对源自晚期乳腺癌和卵巢癌的细胞系进行了检测,以评估各种抗肿瘤药物对其体外增殖的抑制作用。检测在培养早期传代的肿瘤细胞系原代培养物衍生的多个实验培养物中进行。通过比较体外生长抑制50%的情况确定,观察到各细胞系的敏感性存在差异。以药物的2小时血浆水平作为耐药性和敏感性之间的区分阈值,将每种药物对各细胞系的体外有效性与应用于相应患者的化疗临床结果进行比较。总共42例中有39例观察到体外/体内阳性相关性。回顾性评估的17个细胞系对化疗期间试用失败的那些药物耐药。在25例前瞻性试验中,11例在体外和体内均表现出敏感性,此外,11例前瞻性病例在体外和体内均耐药。